ly-3

LY-364947 (HTS466284) is a potent ATP-competitive inhibitor of TGFβR-I.

LY-411575 isomer 3 is an isomer of LY411575. LY411575 is a potent γ-secretase inhibitor.

LY-301664 is a compound which has bio-active.

LY 377604 is an innovative compound functioning as a mixed β3-adrenergic receptor agonist and β1 β2-adrenergic receptor antagonist, showing potential for antidiabetic and anti-obesity effects. In rodent models, LY 377604 has been found to enhance energy expenditure and fat oxidation, reduce blood glucose levels, and induce weight loss while preserving lean body mass. A phase II clinical trial for obesity has been conducted in the United States.

LY-338979 is an impurity of pemetrexedone.

secreted phospholipase A2 (sPLA2) inhibitor

LY-368975 is a potent and selective inhibitor of the norepinephrine (NE) reuptake site. LY-368975 reduces food consumption in rodents.

LY-393675 is an antagonist of metabotropic glutamate receptor (mGluR).

LY-395153 is a novel potentiator of AMPA receptor.

LY-300168, (S)- is a bioactive chemical.

LY-3039478 monohydrate is a bioactive chemical.

LY-326188 is a bio-active chemical.

LY-368842 is a bioactive chemical.

LY-368975 hydrochloride is a bioactive chemical.

LY-393615 free base is a bioactive chemical.

Oritavancin is a novel semisynthetic glycopeptide antibiotics. On August 6, 2014, the FDA approved oritavancin for treatment of skin infections. Oritavancin possesses potent and rapid bactericidal activity in vitro against a broad spectrum of both resistant and susceptible Gram-positive bacteria, including Staphylococcus aureus, MRSA, enterococci, and streptococci.

LY-393615 is a neuronal calcium channel blocker.

LY294002 (SF 1101) is a broad-spectrum inhibitor of PI3K, inhibiting PI3Kα, PI3Kδ, and PI3Kβ (IC50=0.5 0.57 0.97 μM). LY294002 is also an inhibitor of DNA-PK (IC50=1.4 μM) and an inhibitor of CK2 (IC50=98 nM). LY294002 activates apoptosis and autophagy.

LY 195448 (4-(3-(2-Hydroxy-2-phenyl)ethylamino-3-methylbutyl)benzamide) is a substance present in human blood and urine that shows antitumor activity in a mouse tumor model and blocks cells in the mid-stage.

Atomoxetine hydrochloride (LY 139603) is the hydrochloride salt of atomoxetine, a phenoxy-3-propylamine derivative and selective non-stimulant, norepinephrine reuptake inhibitor with cognitive-enhancing activity. Although its precise mechanism of action is unknown, atomoxetine appears to selectively inhibit the pre-synaptic norepinephrine transporter, resulting in inhibition of the presynaptic reabsorption of norepinephrine and prolongation of norepinephrine activity in the synaptic cleft. The effect on cognitive brain function may result in improved attention and decreased impulsivity and activity levels.

Merestinib (LY2801653) is an orally available, small molecule inhibitor of the proto-oncogene c-Met (Ki: 2 nM) with potential antineoplastic activity. Merestinib electively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing the constitutively activated c-Met protein.

Zosuquidar trihydrochloride (LY-335979 trihydrochloride) is a potent modulator of P-glycoprotein-mediated multi-drug resistance with Ki of 60 nM. Phase 3.

Talampanel (LY-300164) is an orally and selective α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor antagonist with anti-seizure activity. Talampanel (IVAX) has neuroprotective effects in rodent stroke models.

LY404039 (pomaglumetad) is an effective agonist of recombinant human mGlu2(Ki =149 nM) mGlu3(Ki =92 nM).